FDA Finalizes 48 Product-Specific Bioequivalence Guidances

Drug Industry Daily
A A
The FDA finalized 48 guidances for generics manufacturers, outlining the recommended studies for demonstrating bioequivalence for dozens of active ingredients and combinations, to assist the industry with generating evidence to support ANDA approvals.

To View This Article:

Login

Subscribe To Drug Industry Daily